EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro

Xiangping Wu, Jing Wu

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-024-04654-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Xiangping Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. Hauptthemen laut MEDLINE: Polo-Like Kinase 1, Protein Serine-Threonine Kinases, Squamous Cell Carcinoma of Head and Neck, Cell Cycle Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polo-like kinase 1 (PLK1) is a critical therapeutic target in the treatment of head and neck squamous cell carcinoma (HNSCC). The objective of this study was to investigate the therapeutic effect of the combination of BI 2536, a PLK1 inhibitor, and erastin, a ferroptosis inducer, in HNSCC.

Methods

The proliferation, invasion, and migration abilities of Tu177 and FaDu cells upon exposure to BI 2536 and erastin, used in combination or alone, were tested. Fe 2+ , glutathione (GSH), and malondialdehyde (MDA) detection kits were used to determine whether the addition of BI 2536 enhanced the accumulation of Fe 2+ and MDA, along with the depletion of GSH. Quantitative real-time PCR, western blot analyses were performed to investigate whether BI 2536 further altered the mRNA and expression level of ferroptosis genes. Furthermore, si PLK1 was used to investigate whether targeting PLK1 gene promoted erastin-induced ferroptosis.

Results

The combination of BI 2536 and erastin exerted a stronger cytotoxicity than treatment with a single agent. Compared with erastin treatment alone, the combination of BI 2536 and erastin lowered the ability of tumor cells to self-clone, invade, and migrate. BI 2536 enhanced the accumulation of Fe 2+ and MDA, and the depletion of GSH. BI 2536 increased erastin-induced changes in ferroptosis-related gene mRNA and expression. Importantly, targeting PKL1 enhanced the anti-cancer effect of erastin.

Conclusion

BI 2536 enhanced the sensitivity of HNSCC cells to erastin, which provides a new perspective for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polo-Like Kinase 1Protein Serine-Threonine KinasesSquamous Cell Carcinoma of Head and NeckCell Cycle ProteinsProto-Oncogene ProteinsHead and Neck NeoplasmsFerroptosisPiperazinesCell ProliferationPteridinesCell MovementHumansCell Line, TumorDrug SynergismProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

BI 2536ErastinHNSCCPLK1

Substanzen

Polo-Like Kinase 1Protein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene ProteinsPiperazinesBI 2536erastinPteridinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
  • Department of Otolaryngology-Head & Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. wujing@ahmu.edu.cn.

Zitieren

APA

Wu, X., & Wu, J. (2024). A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04654-8

Vancouver

Wu X, Wu J. A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04654-8

BibTeX
@article{Wu2024,
  author = {Wu, Xiangping and Wu, Jing},
  title = {A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-024-04654-8}
}
Kostenlos starten →